Review of the guideline of the American College of Physicians on the treatment of osteoporosis
- 948 Downloads
This review, endorsed by the International Osteoporosis Foundation and the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, summarizes several failings of the recent guidelines of the American College of Physicians (ACP) on the treatment of low bone density or osteoporosis to prevent fractures.
The ACP recently issued guidelines for the treatment of low bone density or osteoporosis to prevent fractures.
Literature review and critical review of the ACP guidelines.
The guideline is lacking in scope due to the endorsement of treatment based on T-scores rather than fracture risk assessment and in failure to adequately consider anabolic therapies.
The ACP guideline appears outdated.
KeywordsBone mineral density Fracture risk FRAX Intervention thresholds Treatment guidelines
We are grateful to the Committee of Scientific Advisors and the Committee of National Societies of the International Osteoporosis Foundation (IOF) and the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) for their reviews and endorsement of this manuscript.
Compliance with ethical standards
Conflicts of interest
JAK reports grants from Amgen, Eli Lilly, and Radius Health; non-financial support from Medimaps and Asahi; and other support from AgNovos. JAK is the architect of FRAX but has no financial interest. Professor Cooper reports personal fees from Alliance for Better Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier, Takeda, and UCB. RR has received consulting fees or advisory board fees from Radius Health, Labatec, Danone, and Nestlé. J-YR has received advisory board or speaker fees from Asahi-Kasei, Eli Lilly, IBSA-Genévrier, Nycomed-Takeda, PharmEvo, Radius Health, Roche, Servier, UCB, Will Pharma, and Zodiac.
- 1.Qaseem A, Forciea MA, Mclean RM, Denberg TD, Clinical Guidelines Committee of the American College of Physicians (2017) Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians. Ann Intern Med 166:818–839CrossRefPubMedGoogle Scholar
- 7.World Health Organisation (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843. WHO, GenevaGoogle Scholar
- 16.Kanis JA on behalf of the World Health Organization Scientific Group (2008) Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaborating Centre, University of Sheffield, UK. Available at http://www.shef.ac.uk/FRAX/index.htm
- 18.Royal College of Physicians (1999) Osteoporosis: clinical guidelines for prevention and treatment. Royal College of Physicians, LondonGoogle Scholar
- 19.Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N et al (2017) The National Osteoporosis Guideline Group (NOGG). UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43. https://doi.org/10.1007/s11657-017-0324-5 CrossRefPubMedPubMedCentralGoogle Scholar
- 21.Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y, on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF) (2013) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int 24:23–57CrossRefPubMedGoogle Scholar
- 23.Kanis JA, Harvey NC, Cyrus Cooper C, Johansson H, Odén A, McCloskey EV, the Advisory Board of the National Osteoporosis Guideline Group (2016) A systematic review of intervention thresholds based on FRAX. A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 11:25. https://doi.org/10.1007/s11657-016-0278-z CrossRefPubMedPubMedCentralGoogle Scholar
- 25.Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL et al (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2016—executive summary. Endocr Pract 22:1111–1118CrossRefPubMedGoogle Scholar
- 30.Kanis JA, Jönsson B, Odén A, McCloskey EV (2011) A meta-analysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX®. Osteoporos Int. 22: 2347–2355 with erratum Osteoporos Int 22: 2357–2358Google Scholar
- 39.Shepstone L, Lenaghan E, Cooper C, Clarke S, Fordham R, Gittoes NJ et al (2017) A randomized controlled trial of screening in the community to reduce fractures in older women—the SCOOP Study. Lancet 391(10122):741–747Google Scholar
- 49.Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M et al (2018) Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 33:190–198Google Scholar
- 50.Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR et al (2017) 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 7:513–523. https://doi.org/10.1016/S2213-8587(17)30138-9 CrossRefGoogle Scholar
- 51.Ferrari S, Adachi JD, Lippuner K, Zapalowski C, Miller PD, Reginster JY et al (2015) Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporos Int 26:2763–2771CrossRefPubMedPubMedCentralGoogle Scholar
- 53.Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA et al (2017) Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2017 executive summary. Endocr Pract 23:207–238CrossRefPubMedGoogle Scholar
- 54.Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A et al (2017) Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet S0140-6736(17):32137–32132. https://doi.org/10.1016/S0140-6736(17)32137-2 CrossRefGoogle Scholar
- 58.Bone HG, Cosman F, Miller PD, Williams GC, Hattersley G, Hu M et al (2017) Sustained fracture risk reduction with sequential abaloparatide/alendronate: results of ACTIVEextend. J Bone Miner Res 32(Suppl 1):S25–S26 abstract 1074Google Scholar